Inadequate Sars-Cov-2 Vaccine Effectiveness in Patients with Multiple Myeloma: A Large Nationwide Veterans Affairs Study

Introduction Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, is particularly serious in patients with multiple myeloma (MM), with estimated mortality of over 30% in several studies. In the general population, SARS-CoV-2 vaccination has been demonstrated to be an effective approa...

Descripción completa

Detalles Bibliográficos
Autores principales: Fillmore, Nathanael R, La, Jennifer, Wu, Julie Tsu-Yu, Branch-Elliman, Westyn, Huhmann, Linden, Han, Summer S, Parmigiani, Giovanni, Tuck, David P, Brophy, Mary, Do, Nhan V, Lin, Albert Y, Munshi, Nikhil C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
652.Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701551/
http://dx.doi.org/10.1182/blood-2021-154323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701551/
http://dx.doi.org/10.1182/blood-2021-154323

Ejemplares similares